Friedrich, M. J. et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell, https://doi.org/10.1016/j.ccell.2023.02.008 (2023).

Article  PubMed  Google Scholar 

Dhodapkar, K. M. et al. Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma. Blood Cancer Discov. 3, 490–501 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Samur, M. K. et al. Differences in single cells between BCMA-targeting CAR T-cell therapy responders and non-responders reveals initial resistance and acquired resistance are driven by different factors. Blood 140 (Supplement 1), 2106–2107 (2022).

Article  Google Scholar 

Lancman, G. et al. Bispecific antibodies in multiple myeloma: present and future. Blood Cancer Discov. 2, 423–433 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021).

Article  CAS  PubMed  Google Scholar 

Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 398, 314–324 (2021).

Article  CAS  PubMed  Google Scholar 

Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495–505 (2022).

Article  CAS  PubMed  Google Scholar 

Verkleij, C. P. M. et al. T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. Oncotarget 11, 4076–4081 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Cortes-Selva, D. et al. Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): correlative analyses from MajesTEC-1. Blood 140 (Supplement 1), 241–243 (2022).

Article  Google Scholar 

Haber, L. et al. Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning. Sci. Rep. 11, 14397 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar